Enhanced T-cell therapy targeting NY-ESO-1 regulatory update

FDA granted breakthrough therapy designation to Adaptimmune’s enhanced T-cell therapy targeting NY-ESO-1 to treat inoperable or metastatic synovial sarcoma that expresses cancer/testis antigen 1B ( C...